BioRegenx (BRGX) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q1 FY2026, filed May 20, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BRGX SEC filings page.
BioRegenx Inc (BRGX) reported $1.9M in revenue for fiscal year 2025, down 20.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Revenue is shrinking, but lower costs briefly pushed cash flow positive while balance-sheet pressure still defines the business.
Operating cash flow moved from-$324K in FY2024 to$39K in FY2025, a cash-conversion shift despite continued losses. Net income was still a loss of$1.54M , yet free cash flow reached$30K , showing that earnings and cash temporarily diverged.
Gross margin rose from
A 0.1x current ratio alongside liabilities equal to
Financial Health Signals
We do not publish a peer-relative financial health score for BioRegenx Inc, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
BioRegenx Inc scores -143.04, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $37.1M against total assets of $411K. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioRegenx Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
BioRegenx Inc reported a net loss of $1.5M while generating $39K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
BioRegenx Inc reported an operating loss of $1.2M against $300K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BioRegenx Inc generated $426K in revenue in Q1 2026. This represents a decrease of 17.3% from the same quarter a year earlier. Against the prior quarter it is up 10.5%.
BioRegenx Inc's EBITDA was -$37K in Q1 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
BioRegenx Inc reported a net loss of $26K in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BioRegenx Inc earned $0.00 per diluted share (EPS) in Q1 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
BioRegenx Inc held $46K in cash as of Q1 2026; no long-term debt figure is on record for that period.
Not reported for Q1 2026.
Not reported for Q1 2026.
Margins & Returns
BioRegenx Inc's gross margin was 81.7% in Q1 2026, indicating the percentage of revenue retained after direct costs. This is up 2.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.9 percentage points.
BioRegenx Inc's operating margin was -11.7% in Q1 2026, reflecting core business profitability. This is up 25.7 percentage points from the same quarter a year earlier.
BioRegenx Inc's net profit margin was -6.2% in Q1 2026, showing the share of revenue converted to profit. This is up 45.6 percentage points from the same quarter a year earlier.
Not reported for Q1 2026.
Capital Allocation
None of these metrics is reported for Q1 2026.
BRGX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $426K-17.3% | $386K-16.3% | $508K-14.8% | $446K-39.2% | $515K-6.3% | $460K | $596K | $734K |
| Cost of Revenue | $78K-28.6% | $67K-51.5% | $81K-28.9% | $94K-64.6% | $109K-34.0% | $138K | $114K | $264K-0.3% |
| Gross Profit | $348K-14.2% | $319K-1.2% | $426K-11.5% | $352K-25.0% | $406K+5.7% | $323K | $482K | $470K |
| R&D Expenses | N/A | $32K | $0n/m | $0-100.0% | $0-100.0% | N/A | $0-100.0% | $8K-90.7% |
| SG&A Expenses | $396K-32.9% | $527K-34.8% | $433K+83.1% | $457K-67.3% | $590K-82.7% | $809K | $236K | $1.4M |
| Operating Income | -$50Kn/m | -$936K | -$8Kn/m | -$107Kn/m | -$193Kn/m | N/A | -$327K | -$1.0M |
| EBITDA | -$37Kn/m | N/A | $4Kn/m | N/A | -$180Kn/m | N/A | -$315K | -$1.0M |
| Interest Expense | $77K+3.8% | $82K-47.6% | $72K+6.7% | $71K+7.2% | $74Kn/m | $157K | $68K+3201.7% | $66K+3081.3% |
| Net Income | -$26Kn/m | -$1.0M | -$81Kn/m | -$178Kn/m | -$267Kn/m | N/A | -$395K | -$1.1M |
| EPS (Basic) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00 | $0.00 |
| EPS (Diluted) | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | $0.00n/m | -$0.01n/m | $0.00 | $0.00 |
| Diluted Shares (Avg) | 969M+1.3% | N/A | 961M+0.5% | 959M+0.3% | 957M+24.7% | N/A | 957M | 957M |
Not reported in any period shown, so not listed: Income Tax.
BRGX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $337K-30.2% | $411K-19.2% | $1.2M-93.3% | $1.2M-93.6% | $483K-97.4% | $509K-41.3% | $17.4M+50991.4% | $17.9M+20823.5% |
| Current Assets | $190K-35.3% | $251K-18.4% | $273K-26.4% | $250K-23.5% | $294K-39.4% | $308K-52.8% | $371K+48849.7% | $326Kn/m |
| Cash & Equivalents | $46K-45.2% | $69K+18.8% | $47K-33.0% | $46K-19.1% | $84K-26.7% | $58K-53.4% | $70K | $57K |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 |
| Inventory | $93K-33.9% | $107K-3.7% | $109K-31.1% | $134K-6.7% | $140K-34.2% | $111K-48.9% | $159K | $144K |
| Accounts Receivable | $18K+64.8% | $40K+164.9% | $63K+222.0% | $21K+93.0% | $11K-0.2% | $15K-85.7% | $19K | $11K |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0 |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $7.1M | $7.1M |
| Total Liabilities | $4.9M+20.5% | $4.9M+27.3% | $4.8M+26.7% | $4.8M+30.9% | $4.0M+14.3% | $3.9M+32.4% | $3.8M+34.2% | $3.7M+37.6% |
| Current Liabilities | $4.0M+5.4% | $4.1M+11.9% | $3.9M+11.8% | $3.9M+14.8% | $3.8M+11.8% | $3.6M+30.4% | $3.5M+1362.7% | $3.4M+8090.3% |
| Non-Current Liabilities | $883K+243.1% | $882K+246.3% | $881K+212.1% | $880K+252.5% | $257K+71.5% | $255K+69.7% | $282K-89.1% | $250K-90.5% |
| Long-Term Debt | N/A | $182K-28.6% | N/A | N/A | N/A | $255Kn/m | N/A | N/A |
| Total Equity | -$4.5Mn/m | -$4.5Mn/m | -$3.6M-126.9% | -$3.7M-125.7% | -$3.6M-123.6% | -$3.4Mn/m | $13.6Mn/m | $14.2Mn/m |
| Retained Earnings | -$37.1Mn/m | -$37.1Mn/m | -$36.1Mn/m | -$36.0Mn/m | -$35.8Mn/m | -$35.6Mn/m | -$17.2Mn/m | -$16.8Mn/m |
BRGX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $27K-29.4% | $70Kn/m | -$72Kn/m | $3Kn/m | $38Kn/m | -$11Kn/m | -$31K | -$177K |
| Depreciation & Amortization | $13K+4.6% | N/A | $12K0.0% | N/A | $12K-97.5% | $1.7M | $12K+937.5% | $8K+540.0% |
| Stock-Based Compensation | $7Kn/m | N/A | N/A | N/A | $0-100.0% | N/A | N/A | N/A |
| Capital Expenditures | N/A | $3Kn/m | $6Kn/m | $0n/m | $0-100.0% | $0n/m | $0n/m | $0n/m |
| Free Cash Flow | N/A | $67Kn/m | -$78Kn/m | $3Kn/m | $38Kn/m | -$11Kn/m | -$31K | -$177K |
| Investing Cash Flow | N/A | -$3K-215.3% | -$6Kn/m | -$50Kn/m | $0n/m | $3Kn/m | $0n/m | $0n/m |
| Financing Cash Flow | -$50Kn/m | -$44Kn/m | $71K+52.5% | $17K-86.0% | -$10K-103.7% | -$7K-101.4% | $46K-60.0% | $120K-70.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BRGX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.7%+2.9pp | 82.7%+12.6pp | 84.0%+3.2pp | 79.0%+15.0pp | 78.8%+8.9pp | 70.1% | 80.8% | 64.0% |
| Operating Margin | -11.7%+25.7pp | -242.6% | -1.7%+53.2pp | -24.1% | -37.4% | N/A | -54.9% | -141.7% |
| Net Margin | -6.2%+45.6pp | -263.9% | -15.9%+50.4pp | -40.0% | -51.8% | N/A | -66.3% | -150.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -2.9% | -7.8% |
| Return on Assets | -7.8%+47.4pp | -247.6% | -6.9%-4.6pp | -15.5%-9.3pp | -55.3%-38.4pp | N/A | -2.3% | -6.2% |
| Current Ratio | 0.050.0x | 0.060.0x | 0.070.0x | 0.060.0x | 0.08-0.1x | 0.08-0.1x | 0.11+0.1x | 0.10+0.1x |
| Liabilities-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 0.28 | 0.26 |
| Asset Turnover | 1.26+0.2x | 0.940.0x | 0.43+0.4x | 0.39+0.3x | 1.07+1.0x | 0.91 | 0.03 | 0.04 |
| FCF Margin | N/A | 17.3%+19.7pp | -15.3%-10.0pp | 0.7%+24.9pp | 7.3%+60.8pp | -2.5% | -5.2% | -24.2% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$4.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BioRegenx Inc BRGX | FY2025 | $1.9M | -$1.5M | -83.2% | $97K | — |
| VSee Health Inc VSEE | FY2025 | $14.6M | -$14.7M | N/A | $815K | — |
| Dogecoin Cash Inc DOGP | FY2025 | $739K | -$10.0M | N/A | $1.1M | — |
Where BioRegenx Inc Ranks
Frequently Asked Questions
BioRegenx Inc (BRGX) reported $1.9M in total revenue for fiscal year 2025. This represents a -20.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
BioRegenx Inc (BRGX) revenue declined by 20.8% year-over-year, from $2.3M to $1.9M in fiscal year 2025.
No, BioRegenx Inc (BRGX) reported a net loss of $1.5M in fiscal year 2025, with a net profit margin of -83.2%.
BioRegenx Inc (BRGX) had EBITDA of -$1.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, BioRegenx Inc (BRGX) had $69K in cash and equivalents against $182K in long-term debt.
BioRegenx Inc (BRGX) had a gross margin of 81.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
BioRegenx Inc (BRGX) had an operating margin of -67.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
BioRegenx Inc (BRGX) had a net profit margin of -83.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
BioRegenx Inc (BRGX) generated $30K in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
BioRegenx Inc (BRGX) generated $39K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
BioRegenx Inc (BRGX) had $411K in total assets as of fiscal year 2025, including both current and long-term assets.
BioRegenx Inc (BRGX) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
BioRegenx Inc (BRGX) invested $32K in research and development during fiscal year 2025.
BioRegenx Inc (BRGX) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
BioRegenx Inc (BRGX) had a return on assets of -375.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
BioRegenx Inc (BRGX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to March 31, 2026). The market capitalization is $97K as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
BioRegenx Inc (BRGX) trades at 0.1x sales, its market capitalization divided by $1.8M revenue, trailing 12 months to March 31, 2026. The market capitalization is $97K as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
BioRegenx Inc (BRGX) has negative shareholder equity of -$4.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
BioRegenx Inc (BRGX) has an Altman Z-Score of -143.04, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
BioRegenx Inc (BRGX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
BioRegenx Inc (BRGX) reported a net loss of $1.5M while generating $39K in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
BioRegenx Inc (BRGX) reported an operating loss of $1.2M against $300K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.